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Background: Anaplastic lymphoma kinase-positive non-small cell lung carcinoma patients are generally highly
responsive to the dual anaplastic lymphoma kinase and MET tyrosine kinase inhibitor crizotinib. However, they
eventually acquire resistance to this drug, preventing the anaplastic lymphoma kinase inhibitors from having a
prolonged beneficial effect. The molecular mechanisms responsible for crizotinib resistance are beginning to
emerge, e.g., in some anaplastic lymphoma kinase-positive non-small cell lung carcinomas the development of
secondary mutations in this gene has been described. However, the events behind crizotinib-resistance currently
remain largely uncharacterized. Thus, we report on an anaplastic lymphoma kinase-positive non-small cell lung
carcinoma patient with concomitant occurrence of epidermal growth factor receptor and V-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog mutations upon development of crizotinib-resistance.
Case presentation: A 61-year-old Caucasian never-smoking male was diagnosed with anaplastic lymphoma
kinase -positive pulmonary adenocarcinoma, stage T4N3M1b. Treatment with crizotinib initially resulted in complete
objective response in the thorax and partial response in the abdomen, but after 8 months of therapy the patient
acquired resistance and progressed. Biopsies from new metastases revealed development of epidermal growth factor
receptor and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutations concomitant with the original anaplastic
lymphoma kinase gene rearrangement and without signs of anaplastic lymphoma kinase fusion gene amplification
or secondary anaplastic lymphoma kinase mutations.
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Conclusion: To our knowledge, this is the first report of an anaplastic lymphoma kinase-positive pulmonary
adenocarcinoma, which upon emergence of crizotinib resistance acquired 2 new somatic mutations in the
epidermal growth factor receptor and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog genes, respectively,
concomitant with the original anaplastic lymphoma kinase rearrangement. Thus, these 3 driver mutations, usually
considered mutually exclusive, may coexist in advanced non-small cell lung carcinoma that becomes resistant to
crizotinib, presumably because heterogeneous tumor clones utilize epidermal growth factor receptor and/or
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog signaling to circumvent the inhibition of anaplastic lymph-
oma kinase-mediated signaling by crizotinib. The identification of new targetable somatic mutations by tumor re-
biopsy may help clarify the mechanism behind the development of the acquired crizotinib resistance and pave the
way for combined strategies involving multiple targeted therapies.
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Approximately 85% of newly diagnosed lung cancers are
non-small-cell lung carcinoma (NSCLC). Despite surgery,
radiotherapy and intensive chemotherapy, the median 5-
year survival rate remains around 10% [1]. However,
subsets of NSCLC harboring specific driver mutations af-
fecting EGFR (epidermal growth factor receptor) and ALK
(anaplastic lymphoma kinase) genes can obtain remark-
able benefit from therapies targeting these oncogenic
drivers [2]. Oncogenic ALK gene fusions were identified in
a distinct subpopulation (approximately 5%) of NSCLC
patients [3] typically characterized by adenocarcinoma
histology, young age, no- or light-smoking history, and
in the vast majority of cases, lack of concomitant muta-
tions in EGFR- or KRAS (V-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog) genes or amplification of MET
(mesenchymal-epithelial transition) gene [4]. ALK-posi-
tive NSCLC patients have been shown to be highly re-
sponsive to the oral small-molecule triple ALK, ROS1
and MET tyrosine kinase inhibitor (TKI) crizotinib
(XalkoriW; Pfizer) [5,6]. Based on phase I and II trials,
showing a response rate around 60% in patients with
ALK-rearranged NSCLC, crizotinib was approved as
second-line treatment for this subset of patients by the
US Food and Drug Administration in August 2011 [2]
and by the European Medicine Agency in Autumn 2012.
Moreover, a recent prospective randomized phase III trial
has shown that crizotinib provides longer progression-free
survival, higher response rates, and better quality of life
than chemotherapy when used as second-line in patients
with advanced, previously chemotherapy-treated, ALK-
positive NSCLC [7]. ALK rearrangements typically consist
of a small inversion on chromosome 2p23-21, resulting in
the fusion between exon 20–29 of the ALK gene (encod-
ing the kinase-domain) and exons 1–13 (different variants
due to different breakpoints) in the N-terminal portion of
the Echinoderm Microtubule-associated protein-Like 4
(EML4) gene. Rarer ALK translocation partners, such as
Kinesin Family member 5B (KIF5B) and TRK-fused gene(TFG) have also been reported in NSCLC. Cases of
atypical translocation with partial loss of chromosomal
material, resulting in so called single-red signals by fluor-
escence in-situ hybridization (FISH) analysis of ALK gene
rearrangements in tumor cell nuclei, may also occur [4,8].
These different types of ALK rearrangements result in the
expression of stabilized chimeric ALK fusion-proteins
with constitutive kinase activity and oncogenic properties
[3,5,9,10]. In particular, ALK fusion proteins constitutively
transmit signals via PI3K/AKT/mTOR and RAS/RAF/
MEK/MAPK signaling pathways, leading to enhanced cell
survival and proliferation [3,11].
Although most of ALK-positive NSCLC patients initially
show rapid and effective response to crizotinib [5,6], they
tend to acquire resistance to this targeted drug, a phe-
nomenon also seen with other targeted therapies. This is
an emerging hurdle preventing ALK inhibitors from having
a more prolonged beneficial effect. In some ALK-positive
NSCLC patients the development of secondary point mu-
tations in the ALK kinase domain or ALK fusion gene
amplification have been shown to be responsible for the ac-
quired resistance to crizotinib [9,12,13]. Although, the mo-
lecular mechanisms of acquired crizotinib resistance are
beginning to emerge in some NSCLC patients, in many
other patients they remain unknown [5,9,10,12,14,15]. Pa-
tients, such as the one reported here, acquiring resistance
to ALK-TKI by developing mutations in different genes,
could help clarify the mechanism involved in this process
and the strategies to overcome it.
Case presentation
A 61-year-old Caucasian never-smoking male was referred
to hospital in June 2011 due to respiratory complains and
weight loss. The initial diagnosis was pneumonia but fused
imaging positron emission tomography (PET) and comput-
erized tomography (CT) of the chest revealed an irregular
tumor infiltrate of 5 × 5 cm and possible lymphangitis car-
cinomatosa in the left lung’s upper lobe, enlargement of
bilateral mediastinal and right cervical lymph nodes, and
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played increased uptake of 18F-fluoro-2-deoxy-D-glucose
(18F-FDG). Furthermore, bilateral pleural effusion and dir-
ect tumor invasion into mediastinum and pericardium was
observed. All together, the TNM stage was T4N3M1b.
A small transbronchial biopsy of the pulmonary infil-
trate showed a histology and immunohistochemistry
(IHC) profile (mucin stain+, CK7+, TTF1+, CK5/6−,
p63−) of primary adenocarcinoma (data not shown). Be-
cause of insufficient biopsy material for molecular tests
and quickly deteriorating patient performance, first-line
chemotherapy including carboplatin, vinorelbine, and
bevacizumab was started. Despite an initial partial re-
sponse to this treatment, the disease further progressed
with massive enlargement of mediastinal, retroperiton-
eal, and inguinal lymph nodes (Figure 1A-B). One of the
right inguinal lymph nodes was excised and corresponding
formalin-fixed paraffin-embedded (FFPE) sections were
used to histologically and immunohistochemically confirm
that the metastatic tumor tissue originated from the
pulmonary adenocarcinoma (same morphology of mucin-
producing adenocarcinoma and IHC-profile with CK7+,
TTF1+, CK20−, CDX2−, PSA−). Further sections from
the metastasis were utilized to perform EGFR- and KRAS-
mutation analysis. Nested PCR-amplification followed by
direct sequencing of exon 18–21 of the EGFR gene and byFigure 1 Computerized tomography scanning of thorax (A, C) and pe
response to crizotinib (C, D). A: Multiple malignant enlarged lymph node
enlarged lymph nodes along right iliac vessels (arrow). C: Objective comple
with significant regression of metastatic lymph nodes along iliac vessels (arpyrosequencing of codon 12, 13, 59 and 61 of the KRAS
gene was performed. No EGFR or KRAS mutations were
identified. However, IHC with monoclonal antibody
against the ALK gene product (Novocastra, Clone 5A4),
revealed intense positive staining in the metastatic tumor
tissue (corresponding to 3+ according to the algorithm
proposed by Thunnissen E. et al. [8]) (Figure 2A-B). FISH
analysis of the specimen with dual-color break-apart re-
arrangement probe (Vysis LSI ALK; Abbott Molecular),
detected ALK rearrangement in 40% of the analyzed
tumor cell nuclei (100 tumor cell nuclei analyzed with a
cut-off of 15%). The cell nuclei with rearrangement ap-
peared with one normal fusion signal and an abnormal
single red signal for ALK, characteristic for ALK gene fu-
sion with partial deletion of genetic material [4,8]. The re-
sults provided indication for treating the patient with the
ALK inhibitor crizotinib.
Meanwhile, the patient had been hospitalized because
of sudden deterioration of general condition and dys-
pnea caused by malignant bilateral pleural effusion and
hemodynamically significant, cytologically confirmed,
pericardial effusion requiring echocardiography-guided
pericardiocentesis with 1700 ml fluid decompression.
After improvement of his general condition the patient
started second line treatment with crizotinib. This drug
was provided to the patient through compassionate uselvis (B, D) before initiating crizotinib treatment (A, B) and
s in mediastinum and bilateral pleural effusion (arrows). B: Malignant
te response in thorax without new lesions (arrows). D: Partial response
row).
Figure 2 Metastatic poorly differentiated pulmonary adenocarcinoma before (A, B) and 8 months after starting crizotinib treatment (C,
D). A: In inguinal lymph node before initiation of crizotinib treatment (HE, x20). B: Serial section of sample in A with strongly positive anaplastic
lymphoma kinase immunostaining in the metastatic tumor tissue (5A4 mAb, x20). C: Anaplastic lymphoma kinase-positive immunostaining in
newly appeared inguinal lymph nodal metastasis after 8 months of crizotinib treatment (5A4 mAb, x20). D: Fluorescence in-situ hybridization ana-
lysis of preserved anaplastic lymphoma kinase rearrangement in newly appeared inguinal lymph nodal metastasis after 8 months of crizotinib
treatment. Representative tumor cell nucleus with one normal fusion signal and one single red/orange signal (Oil, x60).
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time. The patient responded positively to crizotinib with
complete remission in the thorax and partial remission
in the abdomen and pelvis (Figure 1C-D).
However, after 8 months of treatment the patient dis-
played massive disease progression in the retroperiton-
eal, pelvic and inguinal lymph nodes, while there was
still complete response in the thorax (Figure 3). In order
to investigate the discrepant response in the thorax and
the retroperitoneum/pelvis and the underlying mecha-
nisms of crizotinib resistance, a new needle biopsy from
the relapsed tumor tissue in the inguinal lymph nodes
was obtained. The histology and IHC-profile were the
same as in the primary lung adenocarcinoma and in the
previous biopsy from inguinal metastasis (same histological
appearance, mucin stain+, CK7+, TTF1+, CK20−, CDX2−,
PSA−; data not shown). Moreover, clinico-radiological ana-
lyses showed no tumors in the gastrointestinal- or genito-
urinary tract. All together the data, despite the relatively
unusual metastatic pattern for a NSCLC, excluded the pos-
sibility of spreading from a second primary adenocarcin-
oma located in an abdominal/pelvic organ. FISH and IHC
revealed that the original ALK rearrangement was still
present, as we detected 60% of examined tumor cells
with single-red ALK signal by FISH and intensely posi-
tive (3+) IHC-staining for ALK protein in the tumor
tissue (Figure 2C-2D). Importantly, we did not detect
amplification of the rearranged ALK gene nor secondary
point mutations in the kinase-domain-coding exons 21–25 of ALK gene, which previously have been reported as
possible mechanisms of acquired crizotinib resistance
[10,12,13]. However, mutations in codon 13 of KRAS
gene (c.38G > A, p.G13D) (Figure 4) and in exon 21 of
EGFR gene (c.2585 T > G, p.L862R) were detected in the
relapsed metastasis (Figure 5). Additional mutation ana-
lysis of genomic DNA re-isolated from the metastatic
inguinal tumor tissue initially examined before the start
of crizotinib treatment, confirmed that this was without
EGFR or KRAS mutations. The results could indicate
that the mutations detected in the relapsed tumor tissue
were newly occurred; however these mutations may
have also emerged as a result of selective pressure in-
duced by crizotinib and 1 or more of the previous ther-
apies. It is indeed possible that these mutations were
already present at baseline in clones of the primary lung
tumor representing so small a fraction of the original
tumor population to go undetected by our sequencing
techniques. Similarly, the co-existence of KRAS and
EGFR mutations in the same tumor tissue could be
interpreted as either double mutation in the crizotinib-
resistant tumor cells or more likely as the occurrence of
two different tumor subpopulations with constitutive
activation of either the EGFR or the KRAS signaling
pathway as different mechanisms of acquired crizotinib-
resistance. Neither of these 2 scenarios could be excluded
by the methods used in our molecular analysis. The EGFR
mutation L862R has to our knowledge not previously
been described in the literature, but given its proximity to
Figure 3 Positron emission tomography scanning after 8 months of crizotinib treatment: still complete response in the thorax but
marked disease progression in the abdomen with newly appeared metastases in retroperitoneal, pelvic and inguinal lymph nodes.
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and L861X), tumor clones bearing the L862R mutation
could also be potentially responsive to EGFR-TKI. Mean-
while, because of rapid worsening while waiting for these
new molecular tests the patient received third-linepemetrexed, showing further progression in abdomen and
pelvis, but still no sign of relapse in the thorax. Unfortu-
nately, the patient rapidly deteriorated and died before be-
ing able to attempt a palliative radiation of the lymph
nodes in pelvis and a fourth-line treatment with erlotinib.
Figure 4 Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
mutation analysis by pyrosequencing. A: V-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog wild type codon 12 + 13 in inguinal
lymph node metastasis before starting crizotinib treatment B: V-Ki-
ras2 Kirsten rat sarcoma viral oncogene homolog mutation (G13D;
GGC > GAC) in newly appeared inguinal lymph nodal metastasis
after 8 months of crizotinib treatment.
Figure 5 Epidermal growth factor receptor mutation analysis by
Sanger sequencing. A: Epidermal growth factor receptor wild type
codon 862 (L862) in inguinal lymph node metastasis before starting
crizotinib treatment B: Epidermal growth factor receptor mutation in
codon 862 (c.2585 T > G; p.L862R) in newly appeared inguinal lymph
nodal metastasis after 8 months of crizotinib treatment.
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Multiple molecular mechanisms are emerging as causes
of acquired resistance to treatment with TKI like crizotinib,
posing new challenges for targeted therapy of NSCLC. We
have presented a patient with advanced, ALK-positive,
EGFR and KRAS wild-type, pulmonary adenocarcinoma,
who after 8 months of response to crizotinib treatment ac-
quired resistance to this drug and progressed rapidly. Re-
biopsy of relapsed metastatic tumor tissue showed newly
emerged somatic mutations in both the KRAS and the
EGFR gene, while the tumor cells still carried the original
ALK rearrangement but without signs of ALK fusion gene
amplification or secondary ALK mutations. These results
indicated that the observed tumor progression was not due
to one of the known mechanisms of acquired crizotinibresistance, i.e. loss of ALK rearrangement, amplification of
ALK fusion gene, or secondary ALK mutations [9,13,15],
but was most likely due to the emergence of concurrent
EGFR and KRAS mutations. To our knowledge, this is the
first report of a concomitant presence of ALK gene re-
arrangement, EGFR mutation, and KRAS mutation in the
same NSCLC patient. Although the vast majority of ALK-
positive pulmonary adenocarcinomas lack concomitant
EGFR- or KRAS-mutations, suggesting that these muta-
tions are mutually exclusive [4,12,16], single cases with
concurrent EML4-ALK fusion gene and EGFR-mutations
have been reported [17-20]. These single patients report-
edly received EGFR-TKI therapy with variable effect, but
none of these patients were treated with crizotinib. In con-
trast, the initial biopsy from the metastatic tumor in the
current case showed only ALK rearrangement and wild-
type EGFR and KRAS, while re-biopsy from a new metasta-
sis at progression after 8 months of crizotinib treatment re-
vealed the appearance of EGFR and KRAS mutations in
addition to an unchanged ALK rearrangement. This sug-
gests that these 3 mutations, typically considered mutually
exclusive [4,12,16], can coexist in some cases of NSCLC
that become resistant to crizotinib in vivo, presumably
because the tumor cells or heterogeneous tumor clones
utilize EGFR and/or KRAS signaling to circumvent the
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emergence of either EGFR or KRAS mutations have been
reported in single NSCLC cases acquiring resistance to cri-
zotinib, both with and without concomitant loss of ALK
gene rearrangement [15].
Metastatic spreading of NSCLC to subdiaphragmatic
lymph nodes, as observed in our case, is relatively un-
common compared to other metastatic sites, such as the
liver. Indeed, a recent study of 1,191 NSCLC patients
consecutively staged by 18F-FDG PET/CT scan, showed
that 6% of them had metastasis to abdominal lymph nodes
and only 0.5% to external iliac lymph nodes [21]. However,
whether the rare occurrence of three simultaneous onco-
genic mutations had an impact on this unusual metastatic
pattern in our patient is unknown.
Together with previous reports, our case clearly un-
derlines the need for re-biopsy in patients who develop
acquired resistance to a TKI such as crizotinib. This
should be done primarily to investigate the mechanisms
behind the acquired resistance, and hopefully identify new
somatic mutations that potentially could be targeted. The
appearance of new targetable somatic mutations could
pave the way for combinatorial therapeutic strategies in-
volving multiple targeted therapies. In this case, however,
the presence of the G13D KRAS mutation could render
the patient resistant to an EGFR-targeting therapy. This
could however not be verified since the patient died before
a new targeted treatment could be initiated. Nevertheless,
the possibility of treating the patient with the EGFR-TKI
erlotinib was considered. Indeed, even if the co-existence
of KRAS and EGFR mutations could be interpreted as
double mutation occurring in the crizotinib-resistant
tumor cells, the possibility of different tumor clones with
activation of EGFR and KRAS signaling as different mech-
anisms of crizotinib-resistance appeared to be an alterna-
tive, perhaps more likely explanation. Furthermore, the
identified L862R EGFR mutation, although not reported
before, was located near mutations known to be sensitive
to EGFR-TKI, such as L858R and L861X. Therefore, the
tumor clone bearing this EGFR mutation could have been
potentially responsive to EGR-TKI therapy. However, a
previously described single case of L862V EGFR mutation
was associated with lack of response to gefitinib and the
same could have been the scenario with the L862R EGFR
mutation. Functional characterization of this and other
rare EGFR mutations is needed in order to elucidate their
impact on treatment with TKI [22].
The appearance of new EGFR and KRAS mutations
could indicate a shift in the oncogenic survival and pro-
liferation dependency from the ALK signaling pathway
to EGFR and/or KRAS pathways in the ALK-TKI resist-
ant cells. Activation of HER-family proteins has been
associated with sustained down-stream signaling in the
presence of ALK-TKI, indicative of the shift in survivaldependency from the ALK signaling pathway to HER-
family-driven pathways in the ALK-TKI resistant cells
[14]. Cell line experiments have also shown that both
EGFR and MET activation and the interaction between
the corresponding signaling pathways may mediate cri-
zotinib resistance [9], suggesting that both signaling by
EGFR and MET may be crucial for the survival of lung
cancer cells upon ALK inhibition. KIT amplification,
auto-phosphorylation of EGFR, and aberrant expression
of other receptor tyrosine kinases have also been postu-
lated by in vitro experiments to cause resistance to cri-
zotinib in ALK-rearranged cancer cells [9,13,15].
However, the mechanisms behind crizotinib resistance
in NSCLC patients are still poorly understood. NSCLC
is increasingly recognized as heterogeneous set of dis-
eases at the morphological and molecular level and these
differences may drive therapeutic decision making. Tumor
heterogeneity, the invariable development of resistance to
targeted monotherapy with TKI, and the occurrence of
multiple driver mutations in TKI-resistant tumor cells, ap-
pear to be problems strictly related to one another and
capable of undermining effective treatment. Whether sep-
arate oncogenic driver subclones with EGFR and KRAS
mutations can arise completely independently, they share
a common progenitor that acquires these drivers inde-
pendently as later events, or both drivers coexist within
the same cell, and then one or other is lost in subclonal
evolution is still unclear. Regardless of which evolutionary
clonal process takes place, the potential role for combina-
torial therapeutics in overcoming crizotinib resistance in
the clinic appears of increasing importance [9,15].Conclusion
Our case demonstrates the utility of tumor re-biopsies
in order to better understand the mechanisms of crizo-
tinib resistance in patients with ALK-rearranged pul-
monary adenocarcinoma. Moreover, our case indicates
that ALK-rearranged NSCLC may possibly acquire re-
sistance to crizotinib through the emergence of concur-
rent somatic mutations in both EGFR and KRAS genes.
The concomitant occurrence of EGFR and KRAS muta-
tions with ALK rearrangement upon crizotinib resistance
suggests that the most effective therapeutic strategy for
ALK-positive lung cancers may ultimately require com-
bined strategies targeting not only ALK gene fusions and
ALK resistance mutations, but also other driver muta-
tions that activate alternative TKI-resistance pathways.Consent
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